L-AmB vs. D-AmB for Cryptococcal Meningitis in Solid-Organ Transplant Recipients

Ninety-day mortality was significantly better with lipid formulations of amphotericin B than with the deoxycholate formulation.

Cryptococcosis is the third most common invasive fungal infection among solid-organ transplant recipients, and among those with cryptococcal disease, meningitis has been documented in 54% to 68%. Although amphotericin B deoxycholate (D-AmB) has been the mainstay of treatment for cryptococcal meningitis (CM) for decades, lipid formulations of amphotericin B (L-AmB) are less nephrotoxic and are associated with fewer infusion-related adverse effects than this agent. Could they lead to improved outcomes in CM?

To explore this issue and to determine other factors associated with outcomes in CM, including the role of 5-fluorocytosine (5-FC), researchers examined data gathered from 2001 through 2007 during a multicenter study. Seventy-five solid-or…

Reviewing Author

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)